Genelux Corporation GNLX
1.92 USD -0.08 (-4.00%)
At closeNov 3, 2026, 7:09 PM EST
1.93 +0.01 +0.52%
After hours · Nov 3, 7:09 PM ET
1.91 Day range 2.06
1.86 52-week range 8.54
- YTD
- -55.96%
- 1 year
- -76.70%
- Market cap
- 86.87M
- Revenue (ttm)
- 8.00K
- EPS (ttm)
- -0.86
- Shares out
- 34.54M
- Forward P/E
- -2.45
- YTD return
- -55.96%
- 1-year return
- -76.70%
- Volume
- 288.00K
- Avg volume
- 358.64K
- Open
- 2.01
- Previous close
- 2.00
- Day's range
- 1.91 – 2.06
- 52-week range
- 1.86 – 8.54
- Price target
- 18.40 (+858.3%)
- Earnings date
- Aug 14, 2024
2Y -1.15 (-37.46%)
Key statistics
- Enterprise value
- 49.05M
- PEG ratio
- 0.00
- Price / sales
- 9929.73
- Price / book
- 3.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.90M
- Total cash
- 33.64M
- Total debt
- 2.21M
- Return on equity
- -88.57%
- Short % of float
- 4.92%
- 50-day average
- 2.72
- 200-day average
- 3.02
Analyst view
Price target (mean) 18.40 +858.3% upside
Now 1.92
- Target (low)
- 8.00
- Target (mean)
- 18.40
- Target (high)
- 30.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.1925.
Financials — quick view
GNLX Revenue — quarterly 0
GNLX Net income — quarterly -9.47M
GNLX EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.19 | -0.19 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Mar 29, 2024 | Dec 1, 2023 | -0.21 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.21 | -0.25 | -0.04 | -19.05% |
| Nov 14, 2023 | Sep 1, 2023 | -0.12 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2024 | Guggenheim | init | — | Buy |
| Aug 27, 2024 | Roth MKM | init | — | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 3, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 31, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- genelux.com
News
Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX) 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy 
12 Health Care Stocks Moving In Friday's After-Market Session 
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate 
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates 
Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday 
Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer 
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer 
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Your note
Sign in to keep a note on GNLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAPPELLO JOSEPH | Officer | Stock Award(Grant) | Dec 17, 2024 | 43,653 |
| MIRABELLI MARY | Director | Stock Award(Grant) | Jul 31, 2024 | 52,001 |
| RYDER SEAN | General Counsel | Stock Award(Grant) | Dec 17, 2024 | 41,388 |
| SMALLING RALPH | Officer | Stock Award(Grant) | Dec 17, 2024 | 31,847 |
| SMITHER JOHN W | Director | Stock Award(Grant) | Jul 31, 2024 | 52,711 |
| SZALAY ALADAR | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 3.89% | 1,343,363 | 3.09M | Sep 29, 2024 |
| Vanguard Group Inc | 2.85% | 984,851 | 2.27M | Sep 29, 2024 |
| Millennium Management Llc | 1.06% | 364,929 | 839.34K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.92% | 316,160 | 727.17K | Sep 29, 2024 |
| Blackrock Inc. | 0.90% | 310,287 | 713.66K | Sep 29, 2024 |
| Bank of America Corporation | 0.63% | 216,781 | 498.60K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.97% | 679,800 | 1.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.82% | 284,119 | 653.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 158,398 | 364.31K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.26% | 90,651 | 208.50K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 61,763 | 142.05K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 51,780 | 119.09K | Oct 30, 2024 |